Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

SDĚLENÍ

Ministerstva zahraničních věcí,

kterým xx xxxx a xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x. a č. 46/2008 Xx. m. x.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2017 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx schválení xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx pro xxx 2018 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx¹⁾.

X novým xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx o xxxxxxx xxxx Xxxxxxx X Xxxxxx xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx I vstoupilo x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2018. Xxx Xxxxxx xxxxxxxxx xxxxxxxxx xxxx xxxxx Přílohy X x xxxxxxxx xxx 5. xxxxxx 2019.

Xxxx xxxxxx nového znění Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X xxxxxx xx 1. xxxxx 2017 x xxxxxxxxx xxx č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx nového znění Xxxxxxx X x xxxx xxxxxxx do xxxxxxx xxxxxx se xxxxxxxxx současně.

SVĚTOVÁ

ANTIDOPINGOVÁ

AGENTURA

SVĚTOVÝ XXXXXXXXXXXXX XXXXX

XXXXXX ZAKÁZANÝCH XXXXX X XXXXX XXXXXXX XXX ROK 2018

MEZINÁRODNÍ XXXXXXXX

Xxxxxxxxx xxxx Xxxxxxx xxxx xxxxxxxxx XXXX x xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx jakýchkoliv xxxxxxxxx xxxx anglickou x xxxxxxxxxxxx verzí xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Seznam bude xxxxxx od 1. xxxxx 2018 

SEZNAM ZAKÁZANÝCH XXXXX X XXXXX XXXXXXX XXX XXX 2018

XXXXXXX ANTIDOPINGOVÝ KODEX

Platný xx 1. xxxxx 2018

XXXXX X XXXXXX XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky xxxxx xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx skupin X1, X2, X4.4, X4.5 x S6(a) a Xxxxxxxxxx xxxxx X1, X2 x X3.

XXXXXXXX XXXXX

X0. NESCHVÁLENÉ XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx pro humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx stadiu xxxxxxx xxxx po xxxxxxxx xxxxxxxxxx, xxxxxxxxxx drogy, xxxxx schválené xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

X1. XXXXXXXXXX XXXXX

Xxxxxxxxxx látky xxxx zakázány.

1. XXXXXXXXXX XXXXXXXXXX STEROIDY (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx);

1-xxxxxxxxxxx (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]xxxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx);

xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17ß-xx);

xxxxxxxxxxx;

xxxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-dihydroxyandrost-4-en-3-on);

kalusteron;

klostebol;

mestanolon;

mesterolon;

metandienon (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Endogenní** XXX, xxxxx xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx);

xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (estr-4-en-3,17-diol);

19-norandrostendion (estr-4-en-3,17-dion);

prasteron (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx xxxxxxxxxx a xxxxxxx, včetně, xxx xx x xxxxxxxx xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Xxxxxxx xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX, např. xxxxxxx, XXX-4033, xxxxxxx x RAD140); xxxxxxx; xxxxxxx a zilpaterol, xxx xx x xxxxxxxx xxxxx na xx.

Xxx xxxxx xxxxxxx xxxx xxxxx: * "exogenní" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx přirozeně neprodukuje. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx produkuje.

S2. PEPTIDOVÉ XXXXXXX, XXXXXXX FAKTORY, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx látky x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx podobnými biologickými xxxxxx xxxx zakázány:

1. Xxxxxxxxxxxxx (XXX) a xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxx, xxxxxx, ale xx x xxxxxxxx pouze xx xx:

1.1 Agonisté xxxxxxxxxxxxxxxxx receptoru, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX (EPO-Fc, methoxypolyethylenglykol-epoetin xxxx (CERA)); XXX-xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx (xxxx. XXXX 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx faktoru (HIF), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (FG-4592); xxxxx.

1.3 Xxxxxxxxxx GATA, xxxx.

X-11706.

1.4 Xxxxxxxxxx TGF - xxxx (XXX - β), např.

luspatercept; sotatercept.

1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx. např.

asialo XXX; xxxxxxxxxxxxx EPO.

2. Xxxxxxxxx xxxxxxx x hormonové xxxxxxxxxx

2.1 Xxxxxxxxxxxxxxxxxx (XX) x xxxxxxxxxxxx xxxxxx (XX) x xxxxxx xxxxxxxxxx xxxxxxx, např. xxxxxxxxx, deslorelin, xxxxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x triptorelin, x xxxx.

2.2 Xxxxxxxxxxxxxx a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx.

2.3 Xxxxxxx xxxxxx (XX), xxxx xxxxxxxxx x uvolňující xxxxxxx, xxxxxx, ale xx s xxxxxxxx xxxxx xx ně:

fragmenty xxxxxxxxx xxxxxxx, např. XXX-9604 x hGH 176-191; xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (XXXX) x xxxx xxxxxxx, xxxx. XXX-1295, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx hormonu (XXX), xxxx. xxxxxxx a xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxxx; uvolňující peptidy xxxxxxxxx xxxxxxx (GHRP), xxxx. xxxxxxxxxxxx, XXXX-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, XXXX-5, GHRP-6 x xxxxxxxxx.

3. Xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx faktorů, xxxxxx, xxx ne x xxxxxxxx pouze na xx:

xxxxxxxxxxxxx xxxxxxx faktory (XXXx);

xxxxxxxxxxxx růstový faktor (XXX);

xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1) x xxxx xxxxxxx

xxxxxxxxxx růstové xxxxxxx (MGF);

růstový xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF);

thymosin- β4 x xxxx xxxxxxxx, xxxx. XX-500;

xxxxxxxxxx-xxxxxxxxxxxx růstový xxxxxx (VEGF).

Další xxxxxxx xxxxxxx x xxxxxxxxxx xxxxxxxxx xxxxxxx ovlivňující xxxxxxx nebo degradaci xxxxxxxx svalů, xxxxx x vaziva, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxx isomerů, xxxx xxxxxxxx.

Xxxxxxxx (ale xx s omezením xxxxx xx ně):

Fenoterol; xxxxxxxxxx; xxxxxxxxx; indakaterol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx xxxx:

• xxxxxxxxx xxxxxxxxxx: maximálně 1600 xxxxxxxxxx xx 24 xxxxx x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx xxxxx xxxxxxx 12 xxxxx po xxxxxxxxx xxxxx;
• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx xxxxx 54 mikrogramů xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 mikrogramů xx 24 hodin.

Přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x moči x xxxxxxxxxxx vyšší než 40 xx/xx nebude xxxxxxxxxx za xxxxxxxxx xxxxxxxxxxxx použití, xxx xxxx xxxxxxxxxx xx xxxxxxxxx laboratorní xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx abnormální výsledek xxx xxxxxxxx xxxxxxxxxxxxx xxxxxx (x xxxxxxxx) xxxxx, xxx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (xxxxxxxxx);

4-xxxxxxxxx-3,6,17-xxxxx (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

2. Selektivní xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

tamoxifen;

toremifen, xxx ne x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx xxxxxxxxxx:

Xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx, ale xx s xxxxxxxx xxxxx xx ně.

4. Xxxxx xxxxxxxxxxxx xxxxxx(x) xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, ale xx x omezením xxxxx xx xx.

5. Metaboiické xxxxxxxxxx:

5.1 Xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX; a Xxxxxxxx Xxxxxxxxx delta xxxxxxxxxxxx xxxxxxxxxxxxxx proliferátory (XXXXδ), xxxx. 2-(2-methyl-4-((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methylthio)phenoxy) xxxxxxxx xxxxxx (GW1516, XX501516);

5.2 xxxxxxxx a xxxxxxxx xxxxxxxx;

5.3 meldonium;

5.4 trimetazidin.

S5. XXXXXXXXX A MASKOVACÍ XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx látky jsou xxxxxxxx, xxxxxx jako xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx x podobnými xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; plasmaexpandery (např. xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, hydroxyethylškrobu x xxxxxxxxx); xxxxxxxxxx, xxx xx x omezením xxxxx na ně.

• Acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxxx; xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx); xxxxxxxxxx x xxxxxxx (xxxx. xxxxxxxxx), xxx xx s xxxxxxxx xxxxx xx xx.

X xxxxxxxx:

• xxxxxxxxxxxx; xxxxxxxxx x xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx (např. dorzolamidu x xxxxxxxxxxxx)

• Xxxxxxxxx xxxxxx xxxxxxxxxxxx xxx zubní xxxxxxxxx

Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx Xxxxxx Xxxxxxxxx kdykoliv xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, bude xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx tuto xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx diuretikum xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. MANIPULACE X XXXX A XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxxxx množství xxxxxxxxx, alogenní (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx systému.

2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx náhražky xxxxxxxx xx hemoglobinu x xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx a xxxxxxxxxxx (XXX13), xxx xx x xxxxxxxx pouze xx xx. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx s xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx následující:

1. Xxxxxxxxx, xxxx Pokus x Xxxxxx, xx xxxxxx xxxxxxx integritu x platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx. Xx xxxxxxxx xxxxxx a/nebo úpravu (xxxx. xxxxxxxxxx) moči, xxx ne x xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx celkem 100 xx xx 12 xxxxx kromě xxxxxx xxxxxxxxx přijatých x xxxxxxx xxxxxxxxxxxx xxxxxxx, xxxxxxxxxxxxx zákroků xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X3. XXXXXX XXXXXX

X důvodu xxxxxxxxxx xx zvýšení xxxxxxxxxxx výkonu xx xxxxxxxx následující:

1. Xxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxxx sekvencí xxxxxx x/xxxx x xxxxxxxxxxxx xxxx epigenetické xxxxxxxx xxxxxx xxxxxxx.

3. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx buněk;

LÁTKY A XXXXXX XXXXXXXX XXX XXXXXXX

Xxxxx kategorií X0 xx X5 x X1 xx M3 xxxxxxxxx xxxx

xxxx Při Xxxxxxx xxxxxxxx i xxxxxxxxxxx xxxxxxx:

XXXXXXXX LÁTKY

S6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx případných xxxxxxxxx xxxxxxx, např. x- x X-, xxxx zakázaná.

Stimulancia zahrnují:

(a) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx uvedeno x tomto odstavci, xx Specifickou xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (ale xx x omezením xxxxx xx ně):

Adrenalin (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (parahydroxyamfetamin);

isomethepten;

katin**;

katinon a xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx a xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (xxxxxxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

X výjimkou:

• klonidinu

• derivátů xxxxxxxxx x xxxxxxx xxxxxx místního/očního xxxxxxx x stimulancií xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2018*.

* Xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Xxxx xxxxx jsou xxxxxxxx xx Xxxxxxxxxxxxxx programu 2018 x xxxxxx xxxxxxxxxx xx Zakázané xxxxx.

** Xxxxx: xx xxxxxxxx xxxxx xxx xxxxxxxxxxx vyšší xxx 5 mikrogramů v 1 xx xxxx.

*** Xxxxxxx x xxxxxxxxxxxxx: xxxx zakázány xxx xxxxxxxxxxx vyšší xxx 10 mikrogramů v 1 xx xxxx.

**** Xxxxxxxxx (epinefrin): xxxx xxxxxxx xxx xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx aplikace xxxx xxxx xxxxxx společně x xxxxxxxxx anestetiky.

***** Xxxxxxxxxxxxx: xx zakázán, xxxxx jeho koncentrace x xxxx je xxxxx xxx 150 xxxxxxxxxx xx mililitr.

S7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx jsou xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. KANABINOIDY

Následující xxxxxxxxxxx xxxx xxxxxxxx:

• Xxxxxxxx xxxxxxxxxxx, xxxx. xxxxx, konopí x marihuana.

• Syntetické xxxxxxxxxxx, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxx kanabimimetika.

Kromě: xxxxxxxxxxxx

X9. GLUKOKORTIKOIDY

Všechny xxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx nebo nitrosvalovou xxxxxxxx xxxx zakázané.

Včetně, xxx ne x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ V URČITÝCH XXXXXXXX

X1. XXXX-XXXXXXXXX

Xxxx-xxxxxxxxx jsou xxxxxxxx pouze x xxxxxxxxxxxxx sportech Xxx Xxxxxxx, a xxx xx to xxxxxxxx x Xxxx soutěž.

• Automobilový xxxxx (FIA)

• Billiard (xxxxxxx xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x akrobatické xxxxxxxx-xxxxx x U-rampa, a xxxxxxxxx X-xxxxx a "xxx air"

• Podvodní sporty (xxxxxxxxx potápění) (XXXX) x xxxxxxxxxxxx konstantní xxxx x xxxxxxxxx xxxx xxx xxxxxxx, xxxxxxxxx apnoe s xxxxxxxxx xxxx bez xxxxxxx, xxxx xxxxxxxxx, xxxx blue, xxxxxxxxxxxx, xxxxxxxx xxxxx, střelba xxxxxxxx na xxxx x xxxxxxxxxx xxxx.

• Xxxxxxx (XXXX, XXX)*

• Xxxxx (WDF)

* Xxxxxxxx také Xxxx xxxxxx

Xxxx-xxxxxxxxx zahrnují následující xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx xxxxx xx xx.

Informace

Právní xxxxxxx x. 36/2019 Sb. x. x. xxxxx účinnosti xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Sb. x. x. byl xxxxxx právním xxxxxxxxx č. 32/2023 Sb. m. s. s xxxxxxxxx xx 22.8.2023.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx v xxxxxxxx xxxx aktualizováno, xxxxx xx xxxx xxxxxx xxxxxxxxx změna xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.

1) Mezinárodní xxxxxx xxxxx dopingu ve xxxxxx, přijatá dne 19. října 2005 x Xxxxxx, xxxx xxxxxxxxx x xxxxxxxxx xxxxx x s xxxxxxxxx xx xxxxxxx xxxxxx pod č. 58/2007 Sb. m. s.

Nové xxxxx xxxxxxxx Xxxxxx xx xxxxxxx xxxxxx xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.